IMPACT

While Gazelle for malaria detection is under development, it is already being used in resource-limited settings for rapid detection of Sickle Cell Disease across 27 countries worldwide including in India

“IHF has helped us continue the momentum and development of our malaria technology. They connected us with many of the top leaders/advisors in malaria in India. This group provided feedback on how to improve our project. IHF has been a real partner alongside us to work to achieve the project goal. The last 2 years were beyond anything we could have expected. We had to stop collecting data, delay the project and were unable to come to India directly. But IHF stayed with us, kept focused on the goal and that made a big difference.” 

Patti White, CEO – Hemex Diagnostics

Related Articles

Hemex Health Awarded $3M NIH Grant to Bring Gazelle Hb Variant Test for Sickle Cell Disease to US Market

These five women entrepreneurs have made path breaking innovations in healthcare

toto togel
toto togel
toto togel